Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study

BACKGROUND: The raw costs of mitomycin C (MMC) and oxaliplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) differ substantially. We sought to compare the morbidity and toxicity profiles associated with the use of oxaliplatin and MMC in patients undergoing cytoreductive surgery (CRS) and HI...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Can J Surg
Hlavní autoři: Benzaquen, Ella, Wang, Yifan, Wiseman, Stephanie, Rosenfeld, Velka, Sideris, Lucas, Dubé, Pierre, Pelletier, Jean-Sebastien, Vanounou, Tsafrir
Médium: Artigo
Jazyk:Inglês
Vydáno: Joule Inc. 2021
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8064255/
https://ncbi.nlm.nih.gov/pubmed/33651573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/cjs.001619
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky